ClinicalTrials.gg
RecruitingNCT06794164eSCCUpdated Oct 20, 2026

Immediate Skin-To-Skin Care For Preterm Infants After Birth

An interventional study of skin to skin care and Standard Care (in control arm) in Effect of Skin to Skin Care in Preterm Neonates and Skin to Skin Care, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to participants aged 0 Minutes to 30 Minutes. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Medical University of Graz · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
0 Minutes to 30 Minutes
Sex
All
01

Study summary

The standard procedure in our centre for preterm neonates is to enable skin-to-skin (SSC) contact within 24 hours after birth. As early SSC immediately after birth might provide numerous positive effects for mothers and their preterm neonates, the objective of this study is to evaluate the feasibility, the safety and the effect of skin-to-skin contact immediately after birth in preterm neonates born with gestational age between 26+0 and 32+0 weeks.

02

Conditions studied

  • Effect of Skin to Skin Care in Preterm Neonates
  • Skin to Skin Care

Keywords

  • skin to skin care
  • preterm neonates
03

In context

Lead sponsor

Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 30 Minutes
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age between 26+0 and 32+0 weeks
  • Written parental

Exclusion criteria

Exclusion Criteria:

  • No intention of full life support
  • Severe congenital malformation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Early skin-to-skin care

    Intervention group

    Procedure: skin to skin care

  • Active comparator
    Standard care group

    Control group

    Procedure: Standard Care (in control arm)

Interventions

  • Procedureskin to skin care

    skin to skin care of preterm infants with their parents immediately after birth

  • ProcedureStandard Care (in control arm)

    skin to skin care within 24 hours after birth

06

What researchers measure

Primary outcomes

  1. vital parameter: Heart rate

    Time frame: during the first 2 hours after birth

  2. vital parameter: Oxygen saturation

    in percent

    Time frame: during the first 2 hours after birth

  3. vital parameter: blood pressure

    systolic, diastolic and mean blood pressure

    Time frame: during the first 2 hours after birth

  4. vital parameter: Temperature

    Time frame: during the first 2 hours after birth

Secondary outcomes

  1. blood sugar

    capillary blood sugar measured 1 hour after birth

    Time frame: 1 hour after birth

  2. FiO2 (Fraction of inspired oxygen)

    Need of oxygen

    Time frame: during first 2 hours after birth

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — It is single center study

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Feb 3, 2027
CompletionEst.
Feb 3, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, oversight details and site details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06794164
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Feb 3, 2025
Primary completion
Feb 3, 2027 (estimated)
Completion
Feb 3, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Nariae Baik-Schneditz, MD, PhD
Contact
nariae.baik@medunigraz.at
+4331638582677
Bernhard Schwaberger, MD, PhD
Contact
bernhard.schwaberger@medunigraz.at
+4331638530018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion